Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

Leukemia

Volumn 21, Issue 1, 2007, Pages 84-92

  Kraus, M ^a   Ruckrich T ^a   Reich, M ^a   Gogel, J ^a   Beck, A ^a   Kammer, W ^a   Berkers, C R ^b   Burg, D ^b   Overkleeft, H ^c   Ovaa, H ^b   Driessen, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBUNIT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MONOTHERAPY; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

EID: 33845532759     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404414     Document Type: Article

References (22)

1. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
2. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639.
3. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
4. Wilkinson KD. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000; 11: 141-148.
5. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805.
6. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996; 35: 3899-3908.
7. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: Clinical application. Clin Chem 2000; 46: 673-683.
8. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000; 18: 538-543.
9. Lindsten K, Menendez-Benito V, Masucci MG, Dantuma NP. A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 2003; 21: 897-902.
10. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 2003; 9: 969-973.
11. Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005; 65: 7896-7901.
12. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005; 2: 357-362.
13. Greiner A, Lautwein A, Overkleeft HS, Weber E, Driessen C. Activity and subcellular distribution of cathepsins in primary human monocytes. J Leukocyte Biol 2003; 73: 235-242.
14. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol 2001; 8: 913-929.
15. Lautwein A, Kraus M, Reich M, Burster T, Brandenburg J, Overkleeft HS et al. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. J Leukocyte Biol 2004; 75: 844-855.
16. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68: 850-858.
17. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999; 20: 3551-3567.
18. Froment C, Uttenweiler-Joseph S, Bousquet-Dubouch MP, Matondo M, Borges JP, Esmenjaud C et al. A quantitative proteomic approach using two-dimensional gel electrophoresis and isotope-coded affinity tag labeling for studying human 20S proteasome heterogeneity. Proteomics 2005; 5: 2351-2363.
19. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998; 392: 618-622.
20. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 2001; 3: 283-288.
21. Chen L, Madura K. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65: 5599-5606.
22. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.